Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Cassava Sciences Inc SAVA announced topline clinical results from its Cognition Maintenance Study (CMS), a small proof-of-concept study designed to demonstrate the effects of simufilam versus placebo ...
Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent manner Results confirm and extend ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Cassava Sciences (NASDAQ: SAVA) is a clinical-stage biopharmaceutical company that is focused on developing novel solutions for Alzheimer’s disease. The company currently has two clinical-stage ...
Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...
An interim analysis of the open-label study of simufilam, Cassava Sciences Inc., of Austin, Texas, showed six months’ treatment with the oral, small molecule improved cognition and behavior scores in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results